TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Sorrento Therapeutics Lead
Play
INVESTING

Sorrento Up on Request for Emergency Authorization for Covid Test

  • By Dan Weil
  • Dec 23, 2020 2:55 PM EST
PRESS RELEASES

Lee's Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation In China For The Treatment Of Recurrent Or Metastatic Cervical Cancer

  • By GlobeNewswire
  • Feb 9, 2021 9:00 AM EST
PRESS RELEASES

Sorrento Announces Subsidiary Company - ADNAB, Inc. - To Develop And Commercialize ADNAB™ Platform Products For Hematological Malignancies And Solid Tumors Based On An Exclusive Technology License From The Mayo Clinic

  • By GlobeNewswire
  • Feb 8, 2021 3:21 PM EST
PRESS RELEASES

Update To 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion Of Stem Cells

  • By GlobeNewswire
  • Jan 31, 2021 5:27 PM EST
PRESS RELEASES

Sorrento Announces Positive Preliminary Results Of Phase 1b Study Of COVI-MSC™ For Treatment Of ICU COVID-19 Patients

  • By GlobeNewswire
  • Jan 26, 2021 7:09 PM EST
PRESS RELEASES

Sorrento To Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein

  • By GlobeNewswire
  • Jan 19, 2021 5:05 PM EST
PRESS RELEASES

Dr. Henry Ji To Participate In A Fireside Chat At The B. Riley Securities Oncology Investor Conference On Jan 20, 2021

  • By GlobeNewswire
  • Jan 19, 2021 2:05 AM EST
PRESS RELEASES

Dr. Henry Ji To Participate In The H.C. Wainwright Bioconnect 2021 Virtual Investor Conference

  • By GlobeNewswire
  • Jan 10, 2021 5:58 PM EST
PRESS RELEASES

Sorrento Announces The Submission Of A Marketing Authorization Application To COFEPRIS (Mexico) For COVI-STIX™ Rapid Detection Test Of SARS-CoV-2 Viral Antigen

  • By GlobeNewswire
  • Dec 30, 2020 12:47 PM EST
Sorrento Therapeutics Lead
INVESTING

Sorrento Up on Request for Emergency Authorization for Covid Test

  • By Dan Weil
  • Dec 23, 2020 2:55 PM EST
PRESS RELEASES

Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application To The FDA For COVI-STIX™ Rapid Test For The Detection Of SARS-CoV-2 Viral Antigen

  • By GlobeNewswire
  • Dec 22, 2020 6:59 PM EST
PRESS RELEASES

Sorrento Receives US FDA Clearance To Proceed With Phase 1 Clinical Trials For STI-2020 (COVI-AMG) In Healthy Volunteers And In Newly Diagnosed COVID-19 Patients

  • By GlobeNewswire
  • Dec 9, 2020 9:00 AM EST
PRESS RELEASES

Sorrento Receives Licensure From The State Of California For Clinical Testing Laboratory (CLIA) Allowing For Clinical Sample Testing

  • By GlobeNewswire
  • Dec 8, 2020 8:05 PM EST
PRESS RELEASES

Sorrento To Participate In The 32nd Piper Sandler Healthcare Investor Conference

  • By GlobeNewswire
  • Nov 29, 2020 8:19 PM EST
Coronavirus: Constantly Surprising Virus Found To Be Heat Tolerant, Self-healing And Very Resilient In Lab Tests
INVESTING

Sorrento Receives $34M Federal Contract for Covid Treatment

  • By Dan Weil
  • Nov 27, 2020 10:37 AM EST
PRESS RELEASES

DARPA And JPEO Award Contract To SmartPharm, A Subsidiary Of Sorrento, For Development Of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies

  • By GlobeNewswire
  • Nov 27, 2020 8:00 AM EST
PRESS RELEASES

Sorrento Announces IND Filing For COVI-DROPS, An Intranasal Formulation Of A High Potency Neutralizing Antibody Against SARS-CoV-2

  • By GlobeNewswire
  • Nov 11, 2020 9:00 AM EST
Wall Street Covid Lead
JIM CRAMER

Mad Money Recap With Jim Cramer: Still Fighting COVID-19

  • By Scott Rutt
  • Nov 10, 2020 8:25 AM EST
PRESS RELEASES

Sorrento Announces FDA IND Filing Today For COVI-AMG Neutralizing And High Potency Antibody Against SARS-CoV-2

  • By GlobeNewswire
  • Nov 9, 2020 9:00 AM EST
Wall Street NYSE Lead
JIM CRAMER

Stimulus and COVID: Cramer's 'Mad Money' Recap (Thursday 10/15/20)

  • By Scott Rutt
  • Oct 15, 2020 8:47 PM EDT
PRESS RELEASES

Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared For A Phase 1 Trial By The FDA To The Pipeline Of COVID-19 Focused Rescue Therapies

  • By GlobeNewswire
  • Oct 12, 2020 5:20 PM EDT
PRESS RELEASES

Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released

  • By GlobeNewswire
  • Oct 9, 2020 7:46 PM EDT
PRESS RELEASES

Scilex Holding Company, A Subsidiary Of Sorrento Therapeutics, Announces Continuous Sales Growth In ZTlido® And Expects To Complete Enrollment On Its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program In 2020

  • By GlobeNewswire
  • Oct 7, 2020 6:00 AM EDT
PRESS RELEASES

Sorrento To Host A R&D Day To Showcase COVID-19 Product Pipeline

  • By GlobeNewswire
  • Oct 4, 2020 6:39 PM EDT
PRESS RELEASES

Sorrento Therapeutics And ViralClear Enter Into Agreement To Explore Combination Antibody Plus Antiviral Therapy Against COVID-19

  • By GlobeNewswire
  • Sep 30, 2020 9:00 AM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.